Review
Endocrinology & Metabolism
Shih-Chun Chang, Chun-Yi Tsai, Keng-Hao Liu, Shang-yu Wang, Jun-Te Hsu, Ta-Sen Yeh, Chun-Nan Yeh
Summary: This case report describes a fatal fulminant hepatitis B reactivation in a male patient with pancreatic neuroendocrine tumors who received everolimus and octreotide treatment. The patient did not receive hepatitis B virus prophylaxis treatment and ultimately died due to acute hepatitis B flare-up-related fulminant hepatic failure.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Medicine, General & Internal
Marcel Zorgdrager, Frans J. C. Cuperus, Robbert J. de Haas
Summary: Hyperammonemia can lead to encephalopathy and pose a diagnostic dilemma. This case report highlights the importance of imaging and biochemical analyses for identifying the underlying causes, in this case a large pancreatic neuroendocrine tumor (PNET) and portosystemic shunts in the liver. The rarity of such cases and the unclear mechanism demonstrate the need for further research. The multimodality imaging approach proves valuable in diagnosing hyperammonemia-induced encephalopathy.
Review
Oncology
Ioannis A. Ziogas, Robin Schmitz, Dimitrios Moris, Cory J. Vatsaas
Summary: Pancreatic neuroendocrine tumors (PNETs) are a type of pancreatic cancer and surgical resection is the only potential curative option. The selection of surgical candidates should be based on tumor functionality, size, location, grade, and stage. Current guidelines recommend resection of any size of functional PNETs and non-functional PNETs >2 cm, while patients with non-functional PNETs <1 cm are advised to undergo watchful waiting. Further research is needed to determine the benefit of surgery for non-functional PNETs of 1-2 cm.
ANTICANCER RESEARCH
(2022)
Article
Endocrinology & Metabolism
Sara Krogh, Henning Gronbaek, Anders Riegels Knudsen, Peter Kissmeyer-Nielsen, Nynne Emilie Hummelshoj, Gitte Dam
Summary: This study aimed to investigate the prognosis and optimal treatment of pancreatic neuroendocrine tumors (PNET). The results showed that larger tumor size, Ki67 index, tumor grade, and stage were predictive of shorter survival, and chromogranin A was a predictor of overall survival. Furthermore, the study supported the active surveillance for small, localized, low-grade PNETs.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Sarah R. Kaslow, Gerardo A. Vitiello, Katherine Prendergast, Leena Hani, Steven M. Cohen, Christopher Wolfgang, Russell S. Berman, Ann Y. Lee, Camilo Correa-Gallego
Summary: This study assessed treatment patterns and outcomes for poorly differentiated pancreatic neuroendocrine carcinoma and found that surgical resection was strongly associated with improved overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Yongzheng Li, Zhiyao Fan, Feifei Zhang, Jian Yang, Ming Shi, Shujie Liu, Yufan Meng, Hanxiang Zhan
Summary: Neoadjuvant therapies can decrease the tumor size and stage of some pNENs, providing some patients with the opportunity for radical resection. However, the optimal treatment regimen for neoadjuvant therapy in pNENs remains unknown based on current data.
FRONTIERS IN ONCOLOGY
(2022)
Article
Surgery
Joseph N. Fahmy, M. Alyssa Varsanik, Daniel Hubbs, Emanuel Eguia, Gerard Abood, Lawrence M. Knab
Summary: This study retrospectively evaluated 87 patients with pNET and found that most patients had long-term survival after surgical resection, with high-grade tumor patients experiencing significantly shorter survival. Minimally invasive surgery was found to be effective in appropriately selected cases.
AMERICAN JOURNAL OF SURGERY
(2021)
Review
Oncology
Chandra K. Maharjan, Po Hien Ear, Catherine G. Tran, James R. Howe, Chandrikha Chandrasekharan, Dawn E. Quelle
Summary: Pancreatic neuroendocrine tumors (pNETs) are rare, slow-growing malignancies with incompletely understood molecular pathogenesis. Current therapies can effectively slow disease progression, but resistance often develops, highlighting the need for a better understanding of disease mechanisms to develop new treatments. Research efforts have identified potential therapeutic targets and expanded model systems for investigating pNETs, with advancements expected to improve patient treatments.
Article
Surgery
Alessandra Pulvirenti, Ammar A. Javed, Theodoros Michelakos, Yurie Sekigami, Jian Zheng, Hannah L. Kalvin, Caitlin A. Mcintyre, Martina Nebbia, Joanne F. Chou, Mithat Gonen, Nitya Raj, Diane L. Reidy-Lagunes, Amer H. Zureikat, Cristina R. Ferrone, Jin He, Alice C. Wei
Summary: This study aimed to describe the recurrence pattern, treatments received, and oncological outcomes of pancreatic neuroendocrine tumors (PanNETs) after curative surgery. The study found that recurrence following surgery is infrequent but reduces survival, with most recurrences being distant and managed with multiple therapies. Prospective studies are needed to establish surveillance strategies and treatment sequences to control the disease and prolong survival.
Article
Medicine, General & Internal
Sven H. Loosen, Karel Kostev, Johannes Eschrich, Sarah Krieg, Andreas Krieg, Tom Luedde, Henning Jann, Christoph Roderburg
Summary: Pancreatic neuroendocrine neoplasms are diagnosed as advanced tumors globally. The majority of patients undergo systemic treatment.
Article
Medicine, General & Internal
Milica Mitrovic-Jovanovic, Nikica Grubor, Stefan Milosevic, Aleksandra Jankovic, Katarina Stosic, Slavenko Ostojic, Aleksandar Ninic, Marjan Micev, Jelena Djokic Kovac
Summary: Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms with diverse clinical and imaging features. Cystic PNETs, in particular, are uncommon tumors that are now more frequently detected due to improved imaging technology. The diagnostic challenge of these cystic lesions presents difficulties for radiologists and pathologists.
Article
Medicine, General & Internal
Swastika Sedhai, Fathia Mohammed, Saveeta Sahtiya, Sadaf Sanaullah, Payal Pritwani, Faraz Saleem, Ayodeji Abere, Muhammad Abu Zar Ghaffari
Summary: Pancreatic neuroendocrine tumors are a rare type of pancreatic tumor with diverse clinical and imaging manifestations. Compared to exocrine pancreatic cancer, patients with PNET have better prognosis and longer survival time. This case report emphasizes the importance of timely diagnosis and intervention for PNET.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Oncology
Karolina Skubisz, Krzysztof Dabkowski, Emilia Samborowska, Teresa Starzynska, Anna Deskur, Filip Ambrozkiewicz, Jakub Karczmarski, Mariusz Radkiewicz, Katarzyna Kusnierz, Beata Kos-Kudla, Tadeusz Sulikowski, Patrycja Cybula, Agnieszka Paziewska
Summary: Pancreatic cancer is a global problem with limited diagnostic and therapeutic options due to a lack of understanding of its pathogenesis. Metabolome analysis revealed unique metabolite profiles for pancreatic ductal adenocarcinoma (PDAC) and neuroendocrine pancreatic tumors (PNET), aiding in the understanding of pancreatic diseases. Disturbed metabolites, including acetylcarnitine C2, serotonin, and glycerophospholipid PC aa C34:1, have the potential to serve as biomarkers for diagnosing and monitoring pancreatic tumors. Serum-circulating metabolites can be easily monitored without invasive procedures, providing valuable information for clinical treatment and dietary strategies.
Article
Gastroenterology & Hepatology
Wentao Zhou, Xu Han, Yuan Ji, Dansong Wang, Dong Xie, Zilong Qiu, Wenhui Lou
Summary: Through deep sequencing, this study identified the genetic alterations in pancreatic neuroendocrine tumor, especially in the metastatic cases, and found increased genomic instability in metastatic tumors. Limited mutated genes were shared between the primary and metastatic lesions.
HEPATOBILIARY SURGERY AND NUTRITION
(2023)
Article
Surgery
Mengqi Liu, Xiaoyan Sun, Zheng Zhang, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo, Shunrong Ji
Summary: The study found that the early-onset pNET group had significantly better overall survival than the typical age-at-onset pNET group, and early surgical resection is beneficial for all pNET patients. Onset age should be considered an important factor in guiding treatment and prognosis in future personalized treatment of pNET.
Article
Surgery
Angela Hill, Franklin Olumba, William Chapman
Summary: Transplantation for HCC is a complex topic, requiring considerations of multiple factors. Balancing tumor size with post-transplant outcome is still an ongoing challenge. Tumor downstaging and the use of new technologies have increased the number of HCC transplants, and these advances can also be applied to other liver tumors.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Olanrewaju A. Eletta, Guergana G. Panayotova, Keri E. Lunsford
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Brianna Ruch, Kayla Kumm, Sandra Arias, Nitin N. Katariya, Amit K. Mathur
Summary: DCD liver transplantation is an underutilized method that can increase access to liver transplantation. With proper donor and recipient selection, matching, surgical technique, and perioperative management, these transplants can achieve similar patient and graft survival rates as DBD liver transplantation. The main limitations in the further growth of DCD liver transplantation are driven by risk aversion, and the current experience is mainly concentrated in large centers. With the advancement of regional and machine perfusion techniques, the definition of a viable DCD liver allograft may be redefined, encouraging wider usage and acceptance.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Lauren Matevish, Madhukar S. Patel, Parsia A. Vagefi
Summary: Downstaging has been shown to be feasible within UNOS-DS criteria, with successful long-term outcomes. Interventional liver-directed therapies have been the standard, but systemic therapies are becoming more effective. Immunotherapy holds promise in downstaging, but further trials are needed to assess feasibility and safety. Individual expertise will continue to guide treatment until more data is available.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Hassan Aziz, Paramita Nayak, David C. Mulligan
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Catherine G. Pratt, Jenna N. Whitrock, Shimul A. Shah, Zhi Ven Fong
Summary: hCCA is a biologically aggressive disease and surgical resection is the only curative treatment. Factors such as patient's physical condition, tumor involvement, residual liver volume, and assessment of metastatic disease heavily influence the feasibility of surgical resection. A multidisciplinary, holistic, and individualized approach is critical for accurately determining resectability and optimizing clinical outcomes for patients with hCCA.
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Sara-Catherine Whitney Zingg, Kristina Lemon
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Christopher J. Sonnenday
SURGICAL CLINICS OF NORTH AMERICA
(2024)
Article
Surgery
Alban Longchamp, Tsukasa Nakamura, Korkut Uygun, James F. Markmann
SURGICAL CLINICS OF NORTH AMERICA
(2024)
